Beta Drugs Quarterly Results for Trading Insights

In Sept 2025, Beta Drugs (BETA) reported revenue ₹106 Cr and net profit ₹12 Cr. For annual financials, live price and key ratios, visit BETA company profile.

Latest Quarter Net Profit
₹12 Cr
QSept 2025
Quarterly Results

BETA Quarterly Results — Revenue, Profit & EPS Highlights

Beta Drugs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with BETA DCF to assess whether the stock is under or overvalued.

  • Revenue of ₹106 Cr in Sept 2025 (+8.2% vs Mar 2025)
  • Net Profit of ₹12 Cr in Sept 2025 (+33.3% vs Mar 2025)
  • EBITDA of ₹24 Cr in Sept 2025 (+26.3% vs Mar 2025)
  • Operating Margin of 21.0% in Sept 2025 (+5.0pp vs Mar 2025)
  • Earnings Per Share of ₹12.10 in Sept 2025 (+35.2% vs Mar 2025)

Beta Drugs Quarterly Results — Revenue, EBITDA, Net Profit & EPS

BETA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Sept 2025 Mar 2025 Jun 2025 Dec 2025 Dec 2024 QoQ YoY
Revenue (₹ Cr) 106 98 103 90 89 8.2% -
Net Profit (₹ Cr) 12 9 12 9 9 - -
EBITDA (₹ Cr) 24 19 23 19 17 - -
EPS (₹) 12.10 8.95 11.59 8.40 9.31 - -
Operating Margin (%) 21.0% 16.0% 20.0% 19.0% 18.0% - -

BETA Share Price Trend — 1-Year Movement Across Quarterly Results

Beta Drugs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse Beta Drugs shareholding analysis to track promoter, FII and institutional holdings.

Profitability Ratios

Profit Margin 11.3%
EBITDA Margin 22.6%
Operating Margin 21.0%
ROE (Annual) 24.4%

Balance Sheet Highlights

Total Assets ₹436 Cr
Total Equity ₹197 Cr
Current Assets ₹331 Cr
Current Liabilities ₹136 Cr

Cash Flow Analysis

Operating Cash Flow ₹36 Cr
Investing Cash Flow ₹-36 Cr
Financing Cash Flow ₹118 Cr
Net Cash Flow ₹118 Cr

Current Market Data

Current Price ₹1400.70
Exchange NSE
Last Updated Apr 13, 2026

BETA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Beta Drugs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Sept 2025
₹396,418.12 Cr 1652.2 14,875 3,125 +10.8% - 21.0% 127.1
Divis Laboratories
Sept 2025
₹162,373.86 Cr 6070.0 2,860 689 +7.1% - 24.1% 233.7
Torrent Pharmaceuti…
Sept 2025
₹140,630.85 Cr 4181.0 3,219 591 +11.3% - 18.4% 238.4
Lupin
Sept 2025
₹106,664.75 Cr 2315.1 6,921 1,485 +23.2% - 21.5% 71.5
Dr Reddys Laborator…
Sept 2025
₹102,844.71 Cr 1235.9 9,135 1,337 +1.1% - 14.6% 76.4
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores